US equities |
AAPL $331.90 ▼-1.90% NVDA $206.65 ▲+2.27% MU $855.10 ▲+2.58% AMD $483.90 ▲+3.65% ORCL $126.19 ▲+5.85% TSLA $398.50 ▼-1.32% MSFT $520.99 ▲+2.74% SPCX $141.31 ▲+3.62%
FinancialContent

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

5.470 +0.150 (+2.82%)
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Shattuck Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs, Inc. Announces Proposed Public Offering
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Phase 1 Results for SL-325
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Participate in Upcoming December Investor Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >